Get the Stockscreener App
0.816
0.34%
-0.0028
After Hours:
.81
-0.006
-0.74%
Cue Biopharma Inc stock is traded at $0.816, with a volume of 34,164.
It is down -0.34% in the last 24 hours and down -9.33% over the past month.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
See More
Previous Close:
$0.8188
Open:
$0.8021
24h Volume:
34,164
Relative Volume:
0.11
Market Cap:
$62.71M
Revenue:
$9.53M
Net Income/Loss:
$-44.61M
P/E Ratio:
-0.8967
EPS:
-0.91
Net Cash Flow:
$-38.32M
1W Performance:
+3.29%
1M Performance:
-9.33%
6M Performance:
-42.94%
1Y Performance:
+7.37%
1-Day Range:
$0.7945
$0.8198
1-Week Range:
$0.76
$0.84
52-Week Range:
$0.45
$1.9891
Cue Biopharma Inc Stock (CUE) Company Profile
Name
Cue Biopharma Inc
Sector
Industry
Phone
617-949-2680
Address
40 GUEST STREET, BOSTON, MA
Compare CUE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
0.816 | 63.47M | 9.53M | -44.61M | -38.32M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
390.76 | 100.71B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.28 | 58.84B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.78 | 61.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
656.89 | 40.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
312.51 | 38.20B | 3.81B | -644.79M | -669.77M | -6.24 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-24 | Initiated | Jefferies | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Nov-21-22 | Initiated | Piper Sandler | Overweight |
| Jan-13-22 | Initiated | H.C. Wainwright | Buy |
| Jan-03-22 | Initiated | Craig Hallum | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Apr-09-20 | Initiated | Stifel | Buy |
| Jan-28-20 | Initiated | BTIG Research | Buy |
| Jan-22-20 | Initiated | JMP Securities | Mkt Outperform |
View All
Cue Biopharma Inc Stock (CUE) Latest News
Is Cue Biopharma Inc. forming a bottoming baseJuly 2025 Patterns & Reliable Momentum Entry Alerts - Newser
Cue Biopharma Inc. stock trend forecast2025 Short Interest & Intraday High Probability Setup Alerts - Newser
Evaluating Cue Biopharma Inc. with trendline analysisWeekly Trade Recap & Verified Momentum Watchlists - Newser
Why Cue Biopharma Inc. stock is on top investor watchlists2025 Volatility Report & Precise Swing Trade Entry Alerts - Newser
Is Cue Biopharma Inc. stock entering bullish territoryTrade Risk Report & Free High Return Stock Watch Alerts - Newser
Predicting Cue Biopharma Inc. trend using moving averagesNew Guidance & Verified Trade Idea Suggestions - Newser
Cue Biopharma Inc. stock daily chart insightsTrend Reversal & AI Forecast Swing Trade Picks - Newser
Cue Biopharma’s Q2 2025: Strategic Advances and Financial Highlights - TipRanks
Regression analysis insights on Cue Biopharma Inc. performanceLong Setup & Real-Time Buy Signal Notifications - Newser
Published on: 2025-08-17 18:02:43 - Newser
Intraday pattern recognizer results for Cue Biopharma Inc.Oil Prices & Verified Technical Signals - Newser
Is Cue Biopharma Inc. trading at a discount2025 Support & Resistance & Target Return Focused Stock Picks - thegnnews.com
Why Cue Biopharma Inc. stock attracts strong analyst attention2025 Macro Impact & Low Drawdown Momentum Ideas - Newser
How to read the order book for Cue Biopharma Inc.Risk Management & Real-Time Buy Signal Alerts - Newser
What makes Cue Biopharma Inc. stock price move sharplyIPO Watch & Free Fast Entry Momentum Trade Alerts - Newser
How to recover losses in Cue Biopharma Inc. stockShare Buyback & Daily Oversold Bounce Ideas - Newser
Will Cue Biopharma Inc. stock go up soon2025 Historical Comparison & Weekly Top Gainers Trade List - Newser
News impact scoring models applied to Cue Biopharma Inc.July 2025 Intraday Action & Daily Stock Trend Reports - Newser
Should you avoid Cue Biopharma Inc. stock right nowFed Meeting & Low Risk High Reward Trade Ideas - thegnnews.com
Using AI based signals to follow Cue Biopharma Inc.Take Profit & Real-Time Chart Breakout Alerts - Newser
How sentiment analysis helps forecast Cue Biopharma Inc.Market Activity Report & Daily Profit Maximizing Trade Tips - Newser
Will Cue Biopharma Inc. stock benefit from interest rate changesJuly 2025 Outlook & Stepwise Entry/Exit Trade Alerts - Newser
Published on: 2025-08-16 02:15:50 - Newser
Order flow analysis tools used on Cue Biopharma Inc.2025 Market Outlook & Verified Short-Term Trading Plans - Newser
Intrinsic Value of Cue Biopharma Inc. Stock: Is It Undervalued or OvervaluedWeekly Profit Report & Low Drawdown Investment Ideas - Newser
How Cue Biopharma Inc. stock performs during market volatilityDip Buying & Stepwise Trade Execution Plans - Newser
Cue Biopharma Inc. Building a Base Near SupportStop Loss & Entry Point Strategy Guides - sundaytimes.kr
What technical models suggest about Cue Biopharma Inc.’s comeback - Newser
Cue Biopharma Reports Q2 2025 Earnings: Collaboration Revenue Exceeds Estimate, Net Loss Narrows - AInvest
Cue Biopharma's Q2 2025 Earnings Beat and Revenue Growth: A Glimpse of Sustainable Turnaround Potential? - AInvest
Cue Biopharma Announces Initiation of Investigator Sponsored Tri - GuruFocus
Cue Biopharma announces initiation of investigator sponsored trial of CUE-102 - TipRanks
Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme - The Manila Times
Dana-Farber Launches Trial of New Immunotherapy Drug for Aggressive Brain Cancer - Stock Titan
Cue Biopharma Inc. Facing Inflection Point in Trend Analysis2025 Buyback Activity & Weekly Top Performers Watchlists - sundaytimes.kr
Cue Biopharma Inc Stock (CUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.22%
3.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):